Antidepressant-like activities of rosiglitazone in the rat forced swim and the mouse tail suspension tests

Amany A.E. Ahmed, Nawal M. Al-Rasheed, Nouf M. Al-Rasheed

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

The current study aimed to investigate the possible antidepressant-like activity of rosiglitazone using the rat forced swimming test (FST) and the mouse tail suspension test (TST), two models predictive of antidepressant activities. In FST, 5 days administration of rosiglitazone (6 or 12 mg/kg, p.o.) significantly decreased the time of immobility without affecting the swimming time. Moreover, rosiglitazone significantly increased climbing, head shaking, and rubbing water away behaviors. These effects were not accompanied by any alteration in the locomotor activity of rats when tested in the open field test (OFT). Additionally, treatment of rats with rosiglitazone significantly reduced plasma corticosterone levels. Administration of fluoxetine (10 mg/kg, p.o.) to the rats for 5 consecutive days, as a positive control, significantly reduced floating and increased swimming time without affecting climbing duration. Moreover, fluoxetine significantly increased head shaking behavior and reduced fecal boli count. However, fluoxetine produced no effect on plasma corticosterone levels. In TST, 5 days administration of rosiglitazone (8.5 or 17 mg/kg, p.o.) significantly reduced the immobility time, this effect was comparable to that observed with fluoxetine. Furthermore, rosiglitazone (17 mg/kg, p.o.) significantly antagonized dexamethazon-induced prolongation of immobility time in mice TST. In conclusion, the present investigation suggests that rosiglitazone possesses a specific antidepressant-like activity in rodents' behavioral models and that this effect may be mediated through reduction of plasma corticosterone level.

Original languageEnglish
Pages (from-to)51-61
Number of pages11
JournalSaudi Pharmaceutical Journal
Volume17
Issue number1
Publication statusPublished - 1 Jan 2009

Fingerprint

rosiglitazone
Hindlimb Suspension
Antidepressive Agents
Fluoxetine
Corticosterone
Head
Locomotion
Rodentia

Keywords

  • Experimental depression
  • Forced swimming test
  • Plasma corticosterone
  • Rosiglitazone
  • Tail suspension test

Cite this

@article{25fbd2df5a18471e97a3e31e439b1479,
title = "Antidepressant-like activities of rosiglitazone in the rat forced swim and the mouse tail suspension tests",
abstract = "The current study aimed to investigate the possible antidepressant-like activity of rosiglitazone using the rat forced swimming test (FST) and the mouse tail suspension test (TST), two models predictive of antidepressant activities. In FST, 5 days administration of rosiglitazone (6 or 12 mg/kg, p.o.) significantly decreased the time of immobility without affecting the swimming time. Moreover, rosiglitazone significantly increased climbing, head shaking, and rubbing water away behaviors. These effects were not accompanied by any alteration in the locomotor activity of rats when tested in the open field test (OFT). Additionally, treatment of rats with rosiglitazone significantly reduced plasma corticosterone levels. Administration of fluoxetine (10 mg/kg, p.o.) to the rats for 5 consecutive days, as a positive control, significantly reduced floating and increased swimming time without affecting climbing duration. Moreover, fluoxetine significantly increased head shaking behavior and reduced fecal boli count. However, fluoxetine produced no effect on plasma corticosterone levels. In TST, 5 days administration of rosiglitazone (8.5 or 17 mg/kg, p.o.) significantly reduced the immobility time, this effect was comparable to that observed with fluoxetine. Furthermore, rosiglitazone (17 mg/kg, p.o.) significantly antagonized dexamethazon-induced prolongation of immobility time in mice TST. In conclusion, the present investigation suggests that rosiglitazone possesses a specific antidepressant-like activity in rodents' behavioral models and that this effect may be mediated through reduction of plasma corticosterone level.",
keywords = "Experimental depression, Forced swimming test, Plasma corticosterone, Rosiglitazone, Tail suspension test",
author = "Ahmed, {Amany A.E.} and Al-Rasheed, {Nawal M.} and Al-Rasheed, {Nouf M.}",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "51--61",
journal = "Saudi Pharmaceutical Journal",
issn = "1319-0164",
publisher = "King Saud University",
number = "1",

}

Antidepressant-like activities of rosiglitazone in the rat forced swim and the mouse tail suspension tests. / Ahmed, Amany A.E.; Al-Rasheed, Nawal M.; Al-Rasheed, Nouf M.

In: Saudi Pharmaceutical Journal, Vol. 17, No. 1, 01.01.2009, p. 51-61.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Antidepressant-like activities of rosiglitazone in the rat forced swim and the mouse tail suspension tests

AU - Ahmed, Amany A.E.

AU - Al-Rasheed, Nawal M.

AU - Al-Rasheed, Nouf M.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The current study aimed to investigate the possible antidepressant-like activity of rosiglitazone using the rat forced swimming test (FST) and the mouse tail suspension test (TST), two models predictive of antidepressant activities. In FST, 5 days administration of rosiglitazone (6 or 12 mg/kg, p.o.) significantly decreased the time of immobility without affecting the swimming time. Moreover, rosiglitazone significantly increased climbing, head shaking, and rubbing water away behaviors. These effects were not accompanied by any alteration in the locomotor activity of rats when tested in the open field test (OFT). Additionally, treatment of rats with rosiglitazone significantly reduced plasma corticosterone levels. Administration of fluoxetine (10 mg/kg, p.o.) to the rats for 5 consecutive days, as a positive control, significantly reduced floating and increased swimming time without affecting climbing duration. Moreover, fluoxetine significantly increased head shaking behavior and reduced fecal boli count. However, fluoxetine produced no effect on plasma corticosterone levels. In TST, 5 days administration of rosiglitazone (8.5 or 17 mg/kg, p.o.) significantly reduced the immobility time, this effect was comparable to that observed with fluoxetine. Furthermore, rosiglitazone (17 mg/kg, p.o.) significantly antagonized dexamethazon-induced prolongation of immobility time in mice TST. In conclusion, the present investigation suggests that rosiglitazone possesses a specific antidepressant-like activity in rodents' behavioral models and that this effect may be mediated through reduction of plasma corticosterone level.

AB - The current study aimed to investigate the possible antidepressant-like activity of rosiglitazone using the rat forced swimming test (FST) and the mouse tail suspension test (TST), two models predictive of antidepressant activities. In FST, 5 days administration of rosiglitazone (6 or 12 mg/kg, p.o.) significantly decreased the time of immobility without affecting the swimming time. Moreover, rosiglitazone significantly increased climbing, head shaking, and rubbing water away behaviors. These effects were not accompanied by any alteration in the locomotor activity of rats when tested in the open field test (OFT). Additionally, treatment of rats with rosiglitazone significantly reduced plasma corticosterone levels. Administration of fluoxetine (10 mg/kg, p.o.) to the rats for 5 consecutive days, as a positive control, significantly reduced floating and increased swimming time without affecting climbing duration. Moreover, fluoxetine significantly increased head shaking behavior and reduced fecal boli count. However, fluoxetine produced no effect on plasma corticosterone levels. In TST, 5 days administration of rosiglitazone (8.5 or 17 mg/kg, p.o.) significantly reduced the immobility time, this effect was comparable to that observed with fluoxetine. Furthermore, rosiglitazone (17 mg/kg, p.o.) significantly antagonized dexamethazon-induced prolongation of immobility time in mice TST. In conclusion, the present investigation suggests that rosiglitazone possesses a specific antidepressant-like activity in rodents' behavioral models and that this effect may be mediated through reduction of plasma corticosterone level.

KW - Experimental depression

KW - Forced swimming test

KW - Plasma corticosterone

KW - Rosiglitazone

KW - Tail suspension test

UR - http://www.scopus.com/inward/record.url?scp=61849123313&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 51

EP - 61

JO - Saudi Pharmaceutical Journal

JF - Saudi Pharmaceutical Journal

SN - 1319-0164

IS - 1

ER -